Roivant Sciences
Quarterly Financials
| Values in thousands | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 |
|---|---|---|---|---|
Revenue | $1,571 | $2,170 | $7,570 | $9,018 |
Gross Profit | 1,460 | 2,016 | 7,365 | 8,759 |
EBITDA | -158,122 | -283,824 | -283,540 | -271,460 |
EBIT | -159,044 | -284,922 | -284,965 | -274,381 |
Net Income | -113,519 | -223,355 | -206,475 | 169,381 |
Net Change In Cash | 1,571 | 2,170 | 7,570 | 9,018 |
Free Cash Flow | -193,512 | -208,418 | -173,376 | -209,078 |
Cash | 1,237,010 | 1,238,459 | 2,715,411 | 1,990,683 |
Basic Shares | 680,947 | 680,286 | 707,299 | 722,716 |
Annual Financials
| Values in thousands | 2025-03-31 | 2024-03-31 | 2023-03-31 | 2022-03-31 |
|---|---|---|---|---|
Revenue | $29,053 | $32,713 | $61,280 | $55,286 |
Gross Profit | 28,142 | 31,114 | 48,152 | 46,320 |
EBITDA | -1,099,610 | -802,892 | -1,178,009 | -910,774 |
EBIT | -1,113,681 | -824,928 | -1,196,866 | -916,706 |
Net Income | -171,981 | 4,348,926 | -1,009,030 | -845,262 |
Net Change In Cash | 29,053 | 32,713 | 61,280 | 55,286 |
Cost of Revenue | -388,200 | -67,642 | ||
Free Cash Flow | -844,050 | -766,650 | -856,083 | -695,165 |
Cash | 2,715,411 | 6,535,706 | 1,676,813 | 2,060,400 |
Basic Shares | 725,396 | 831,049 | 712,791 | 669,753 |
Earnings Calls
| Quarter | EPS |
|---|---|
2025-12-31 | $0 |
2025-09-30 | -$0.17 |
2025-06-30 | -$0.25 |
2025-03-31 | -$0.29 |
